Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... National Restaurant Association’s NRA Show 2015, in Chicago, ... the company will be available to share information ...
(Date:4/24/2015)... April 24, 2015 /CNW Telbec/ - Mirego, leader in mobile ... making of three mobile app extensions for the all new ... its clients, Familiprix, OMSignal and MediaMiser, these extensions will reinvent ... functions designed specifically for wrist use.  Available ... is a highly customizable tactile smartwatch that makes for an ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of ... the lighting market. In recent months, there ... in emerging markets such as Russia, South America, ... applications such as streetlight and area lighting, tunnel ... launched in 2005 the Acrich technology from Seoul ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
Breaking Biology Technology:DryLet to Showcase Bio-React at the National Restaurant Association’s NRA Show 2015 May 16-19, 2015 in Chicago, Illinois 2Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3
... Hu of China - Source: Getty Images The Olympics ... four years. They're held every year. Though this is still ... as the pervasive growth of the industry becomes part of ... every four years and last two weeks, the biotech Olympics ...
... MADISON, Wis. - Ownership and accountability is the way ... 448-bed community hospital in Madison that provides medical care ... living facility, laboratories and a home health care service. ... Methodist Hospital in 1987, Meriter includes more than 430 ...
... trend three years ago many companies cut their information ... the price of computers dropped, allowing businesses to inexpensively ... grew. Many IT staffers are wary of returning to ... looked to begin working as an outside IT source, ...
Cached Biology Technology:The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4Expetec expands IT staff services in Wisconsin 2Expetec expands IT staff services in Wisconsin 3
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... screening the genome of hundreds of thousands of individuals ... more than 100 regions in the genome to the ... Molecular Biology Laboratory (EMBL) and the University of Heidelberg, ... taking these results one step further by pinpointing the ...
... 2013) "Green" chemistry developed at Rice University is at ... waste into fatty acids, and then into fuel. The ... recently announced $25 million United States Department of Agriculture project ... products from switchgrass and forestry residues and from a new ...
... have been a source of great controversyparticularly in Europebut ... scientific evidence about the health and ecological impacts of ... field site dedicated for use in GM crop studies ... interested in pursuing crop biotechnology, according to an article ...
Cached Biology News:Zeroing in on heart disease 2Modified bacteria turn waste into fat for fuel 2Modified bacteria turn waste into fat for fuel 3Fighting GM crop vandalism with a government-protected research site 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Biology Products: